Belgium
· Delayed Price · Currency is EUR Celyad Oncology Statistics
Total Valuation
Celyad Oncology has a market cap or net worth of EUR 28.67 million. The enterprise value is 23.43 million.
| Market Cap | 28.67M |
| Enterprise Value | 23.43M |
Important Dates
The next estimated earnings date is Wednesday, April 2, 2025.
| Earnings Date | Apr 2, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Celyad Oncology has 41.43 million shares outstanding. The number of shares has increased by 55.53% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 41.43M |
| Shares Change (YoY) | +55.53% |
| Shares Change (QoQ) | +43.60% |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 0.18% |
| Float | 14.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 8.78 |
| P/TBV Ratio | 8.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.02 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.28 |
Financial Position
The company has a current ratio of 3.59, with a Debt / Equity ratio of 0.30.
| Current Ratio | 3.59 |
| Quick Ratio | 3.03 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.10 |
| Interest Coverage | -63.78 |
Financial Efficiency
Return on equity (ROE) is -361.90% and return on invested capital (ROIC) is -167.43%.
| Return on Equity (ROE) | -361.90% |
| Return on Assets (ROA) | -38.87% |
| Return on Capital (ROIC) | -167.43% |
| Revenue Per Employee | 4,000 |
| Profits Per Employee | -430,667 |
| Employee Count | 19 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +92.22% in the last 52 weeks. The beta is 1.51, so Celyad Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 1.51 |
| 52-Week Price Change | +92.22% |
| 50-Day Moving Average | 0.56 |
| 200-Day Moving Average | 0.36 |
| Relative Strength Index (RSI) | 51.07 |
| Average Volume (20 Days) | 65,775 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Celyad Oncology had revenue of EUR 72,000 and -7.75 million in losses. Loss per share was -0.22.
| Revenue | 72,000 |
| Gross Profit | 38,000 |
| Operating Income | -7.78M |
| Pretax Income | -7.82M |
| Net Income | -7.75M |
| EBITDA | -7.44M |
| EBIT | -7.78M |
| Loss Per Share | -0.22 |
Balance Sheet
The company has 6.23 million in cash and 989,000 in debt, giving a net cash position of 5.24 million or 0.13 per share.
| Cash & Cash Equivalents | 6.23M |
| Total Debt | 989,000 |
| Net Cash | 5.24M |
| Net Cash Per Share | 0.13 |
| Equity (Book Value) | 3.27M |
| Book Value Per Share | 0.08 |
| Working Capital | 6.25M |
Cash Flow
In the last 12 months, operating cash flow was -9.70 million and capital expenditures -583,000, giving a free cash flow of -10.29 million.
| Operating Cash Flow | -9.70M |
| Capital Expenditures | -583,000 |
| Free Cash Flow | -10.29M |
| FCF Per Share | -0.25 |
Margins
| Gross Margin | 52.78% |
| Operating Margin | -10,806.94% |
| Pretax Margin | -10,854.17% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Celyad Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -55.53% |
| Shareholder Yield | -55.53% |
| Earnings Yield | -31.88% |
| FCF Yield | -35.88% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Celyad Oncology has an Altman Z-Score of -39.85. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -39.85 |
| Piotroski F-Score | n/a |